Dimebolin Compounds for Epilepsy Seizure Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy and epileptic syndromes are inadequate in effectively managing seizures and long-term prognosis, as they often have adverse effects and limited efficacy due to the complex mechanisms of seizure initiation and maintenance in the brain.
Innovation Solution
Administration of dimebolins, which modulate AMPA and NMDA glutamate receptors, inhibit L-type calcium channels, and block mitochondrial permeability transition pores, offering a multi-mechanism approach to reduce seizure activity and neuronal damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-epileptic drugs are administered, then seizure frequency may be reduced, but adverse effects increase and long-term efficacy is limited
Solution Approach 1:
The patent changes the chemical structure parameters of existing anti-epileptic drugs by introducing fluorine atoms at specific positions (e.g., 2-fluoro-5-(trifluoromethyl)phenyl group) to modify pharmacokinetic and pharmacodynamic properties, thereby improving efficacy while reducing adverse effects
Solution Approach 2:
The patent creates composite molecular structures by combining specific aromatic groups (fluorinated phenyl), heterocyclic rings (pyrimidine, pyridine), and functional groups (amino, oxo) to generate new compounds with optimized therapeutic profiles that balance efficacy and safety
2Reliability
If higher doses of anti-epileptic drugs are administered, then seizure control may improve, but toxicity increases
Solution Approach 1:
The patent optimizes dosage parameters by administering the new compounds at lower doses (e.g., 1-50 mg/kg body weight) compared to conventional drugs, achieving effective seizure control with reduced toxicity due to improved pharmacokinetic properties of the fluorinated structures
Solution Approach 2:
The patent designs compounds with optimized metabolic stability allowing for intermittent dosing regimens, where the drugs are rapidly eliminated after serving their therapeutic purpose, reducing cumulative toxicity while maintaining effective seizure control
3Reliability
If current anti-epileptic treatments are used, then some seizure types may be controlled, but long-term prognosis remains poor due to limited mechanisms of action
Solution Approach 1:
The patent creates multi-functional compounds that can simultaneously modulate multiple ion channels (sodium, calcium, potassium channels) and neurotransmitter systems, providing broad-spectrum anti-epileptic activity across different seizure types and mechanisms, thereby improving long-term prognosis through versatile action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Dimebolins demonstrate therapeutic effectiveness in reducing seizure frequency and severity, improving long-term prognosis by selectively targeting NMDA sites and minimizing adverse effects, while also protecting mitochondria from degradation during seizures.
Implementation Method 1
dimebolins, which modulate AMPA and NMDA glutamate receptors
Implementation Method 2
inhibit L-type calcium channels
Implementation Method 3
block mitochondrial permeability transition pores, offering a multi-mechanism approach to reduce seizure activity and neuronal damage
Data Source
AI summary
Compositions and methods for treating epilepsy and epileptic syndromes are described herein. The compositions and methods include therapeutically effective amounts of one or more dimebolins, or pharmaceutically acceptable salts thereof.